Starboard Value says Bristol-Myers Squibb's (BMY) proposed merger with Celgene (CELG) is ill-advised

February 28, 2019 9:42 AM
Starboard Value LP, a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE: BMY), today announced that it has delivered ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Corporate News Hedge Funds

Next Articles